Abbott Laboratories (ABT): Gross Profit

Revenue minus cost of revenue for the same annual period and currency, computed by TickerFacts from the filed figures. The issuer may report gross profit or margin on a different basis.

Computed by TickerFacts from revenue minus cost of revenue. This may differ from the issuer's reported gross profit or margin; check the revenue and cost definitions.

$25.01B

Year ended 2025-12-31

$25.39B

Trailing 12 months to 2026-03-31

+0.7%

3-year compound annual growth

+5.0%

5-year compound annual growth

2016-12-31 Gross Profit (USD) 2025-12-31

Period ended	Gross Profit	Change YoY	Source filing
2025-12-31	$25.01B	+7.6%	2026-02-20, From 2025-01-01
2024-12-31	$23.24B	+5.0%	2026-02-20, From 2024-01-01
2023-12-31	$22.13B	-9.7%	2026-02-20, From 2023-01-01
2022-12-31	$24.51B	-0.1%	2025-02-21, From 2022-01-01
2021-12-31	$24.54B	+25.2%	2024-02-16, From 2021-01-01
2020-12-31	$19.61B	+5.0%	2023-02-17, From 2020-01-01
2019-12-31	$18.67B	+4.5%	2022-02-18, From 2019-01-01
2018-12-31	$17.87B	+19.3%	2021-02-19, From 2018-01-01
2017-12-31	$14.98B	+27.4%	2020-02-21, From 2017-01-01
2016-12-31	$11.76B	n/a	2019-02-22, From 2016-01-01

Gross Profit at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Gross Profit	Change YoY
Abbott Laboratories (ABT)	2025-12-31	$25.01B	+7.6%
AbbVie Inc. (ABBV)	2025-12-31	$42.96B	+8.9%
Pfizer Inc (PFE)	2025-12-31	$46.51B	+1.6%
Merck & Co., Inc. (MRK)	2025-12-31	$48.63B	-0.7%
Eli Lilly & Co (LLY)	2025-12-31	$54.13B	+47.8%
Johnson & Johnson (JNJ)	2025-12-28	$63.94B	+4.2%
Teva Pharmaceutical Industries Ltd (TEVA)	2025-12-31	$8.94B	+10.8%
Viatris Inc (VTRS)	2025-12-31	$5.01B	-10.8%
Vertex Pharmaceuticals Inc (VRTX)	2025-12-31	$10.35B	+9.1%

Compare ABT, ABBV, PFE, MRK side by side · Screen every company in Pharmaceutical Preparations ↗